Amicus Spins Out Rare Disease Gene Therapy Pipeline, Raises $200m

 
• By Joseph Haas
  
Empty dirt road which splits in two, concept for life choices or decisions
Amicus will split out its gene therapy R&D into Caritas
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business